A Phase 2 interventional study of Maralixibat in Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome and Cholestatic Liver Disease, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 14 sites in 7 countries. Open to participants aged 0 Days to 364 Days. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Cholestasis, progressive familial intrahepatic 1 · United States.
Among the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States, this one is the only one that started in 2021, is one of 2 in phase 2, and was the 9th registered.
33 studies on the registry are indexed under Cholestasis, progressive familial intrahepatic 1; 13 are open to participants now.
Browse Cholestasis, progressive familial intrahepatic 1 studies →1 of the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States is open now. Recruiting first, the newest first:
Mirum Pharmaceuticals, Inc. · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Cholestasis, progressive familial intrahepatic 1 studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.
This study: 0 Days to 364 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2021.
This study's enrollment of 27 is below the median of 60 across 11 interventional studies indexed under Cholestasis, progressive familial intrahepatic 1.
Median enrollment 84 across the 5 interventional studies, 250 across the 4 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 5 most frequent:
Mirum Pharmaceuticals, Inc. is the lead sponsor of 40 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
Mirum Pharmaceuticals, Inc. has 8 studies filed under Cholestasis, progressive familial intrahepatic 1 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in children \<12 months of age with Alagille Syndrome [ALGS] or Progressive Familial Intrahepatic Cholestasis [PFIC].
This is an open label study where all participants will receive maralixibat treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Participants will receive up to 600 μg/kg twice daily (PFIC) or up to 400 μg/kg once daily (ALGS) over 13 weeks in the core study and for the duration of the Long Term Extension (LTE) where applicable.
Drug: Maralixibat
Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL) * 400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base * 600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base
Also known as: Formerly LUM001 and SHP625
Frequency of Treatment-emergent Adverse Events [TEAEs]
TEAEs = Treatment-emergent Adverse Events
Time frame: From Baseline through to Week 13
Change in Fasting Serum Bile Acid (sBA) Levels
sBA = serum bile acid
Time frame: From Baseline through to Week 13
To Evaluate the Effect on Liver Enzymes (ALT)
ALT= alanine aminotransferase.
Time frame: From Baseline through to Week 13
Change From Baseline to Week 13 in Lipid-Soluble Vitamins (LSVs) - Vitamin E
Change from baseline to Week 13 in vitamin E.
Time frame: From Baseline through to Week 13
Maximum Level of Maralixibat Concentration in Plasma From Baseline to Week 13 for ALGS
BID=twice daily; QD=once daily. Systemic concentrations of maralixibat in plasma were determined at the following visits: * Approximately 2.5 hours after the morning dose at Week 0/Day 1 of dosing * Before dosing and \~2.5 hours after the morning dose at Week 6, Week 10, and Week 13 Stable dosing occurred at 400 μg/kg QD for ALGS or at the highest tolerated dose. Note: The values added in section Measured Values are for maralixibat dose of 400 µg/kg QD.
Time frame: At Baseline, Week 6, Week 10, Week 13 or Early Termination Visit
To Evaluate the Effect on Liver Enzymes (AST)
AST= aspartate aminotransferase
Time frame: From Baseline through to Week 13.
To Evaluate the Effect on Bilirubin
Bilirubin
Time frame: From Baseline through to Week 13
Change From Baseline to Week 13 in Lipid-Soluble Vitamins (LSVs) - Vitamin A
Change from baseline to Week 13 in vitamin A
Time frame: From Baseline through to Week 13
Change From Baseline to Week 13 in Lipid-Soluble Vitamins (LSVs) - Vitamins D and K
Change from baseline to Week 13 in vitamins D and K.
Time frame: From Baseline through to Week 13
Maximum Level of Maralixibat Concentration in Plasma From Baseline to Week 13 for PFIC
BID=twice daily; QD=once daily. Systemic concentrations of maralixibat in plasma were determined at the following visits: * Approximately 2.5 hours after the morning dose at Week 0/Day 1 of dosing * Before dosing and \~2.5 hours after the morning dose at Week 6, Week 10, and Week 13 Stable dosing occurred at 300 μg/kg QD, 300 μg/kg BID and 600 μg/kg BID for PFIC or at the highest tolerated dose. Note: The values added in section Measured Values are for maralixibat dose of 600 µg/kg BID.
Time frame: At Baseline, Week 6, Week 10, Week 13 or Early Termination Visit
A total of 27 participants were enrolled in the study, across 10 sites in 6 countries (Belgium, Brazil, France, Poland, United Kingdom, and United States), 17 patients in the ALGS Cohort and 10 in the PFIC Cohort.
| Milestone | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| Started | 17 | 10 |
| Completed | 16 | 9 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 |
TEAEs = Treatment-emergent Adverse Events
| Participants | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| At least one TEAE | 16 | 10 |
| TEAE related to study drug | 4 | 3 |
| Grade ≥3 TEAE | 6 | 1 |
| Grade ≥3 TEAE related to study drug | 0 | 0 |
| Serious TEAE | 6 | 2 |
| Serious TEAE related to study drug | 0 | 0 |
| TEAE that led to study discontinuation | 0 | 1 |
| TEAE that led to death | 0 | 0 |
sBA = serum bile acid
| µmol/L | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| Baseline | 292.81 ± 218.756 | 228.32 ± 107.52 |
| Week 13 | 172.49 ± 109.924 | 138.90 ± 91.610 |
| Change from Baseline | -75.68 ± 115.669 | -77.49 ± 128.616 |
ALT= alanine aminotransferase.
| U/L | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| ALT, U/L Baseline | 167.35 ± 106.018 | 149.00 ± 110.108 |
| ALT, U/L Week 13 | 256.87 ± 190.732 | 80.50 ± 41.946 |
| ALT, U/L Change from Baseline | 99.00 ± 190.981 | -27.00 ± 25.031 |
Change from baseline to Week 13 in vitamin E.
| mg/L | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| Vitamin E mg/L Baseline | 6.54 ± 5.351 | 2.78 ± 2.149 |
| Vitamin E mg/L Week 13 | 5.99 ± 5.084 | 3.98 ± 3.658 |
| Vitamin E mg/L Change from Baseline | -0.46 ± 2.214 | 0.92 ± 1.422 |
BID=twice daily; QD=once daily. Systemic concentrations of maralixibat in plasma were determined at the following visits: * Approximately 2.5 hours after the morning dose at Week 0/Day 1 of dosing * Before dosing and \~2.5 hours after the morning dose at Week 6, Week 10, and Week 13 Stable dosing occurred at 400 μg/kg QD for ALGS or at the highest tolerated dose. Note: The values added in section Measured Values are for maralixibat dose of 400 µg/kg QD.
| ng/mL | Maralixibat: ALGS |
|---|---|
| Maximum Level of Maralixibat Concentration in Plasma From Baseline to Week 13 for ALGS | 0.5576 ± 0.6107 |
AST= aspartate aminotransferase
| U/L | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| AST, U/L Baseline | 184.12 ± 105.42 | 159.10 ± 97.034 |
| AST, U/L Week 13 | 236.8 ± 142.540 | 85.71 ± 36.068 |
| AST, U/L Change from Baseline | 69.27 ± 136.827 | -30.43 ± 32.264 |
Bilirubin
| µmol/L | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| Total bilirubin, µmol/L Baseline | 142.54 ± 102.323 | 41.02 ± 23.651 |
| Total bilirubin, µmol/L Week 13 | 114.89 ± 102.789 | 18.51 ± 16.720 |
| Total bilirubin, µmol/L Change from Baseline | -22.85 ± 46.252 | -18.01 ± 18.781 |
Change from baseline to Week 13 in vitamin A
| umol/L | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| Vitamin A umol/L Baseline | 1.78 ± 1.189 | 1.50 ± 0.991 |
| Vitamin A umol/L Week 13 | 2.08 ± 1.031 | 2.32 ± 0.884 |
| Vitamin A umol/L Change from Baseline | 0.45 ± 0.678 | 0.61 ± 0.878 |
Change from baseline to Week 13 in vitamins D and K.
| nmol/L | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| Vitamin D nmol/L Baseline | 62.64 ± 58.563 | 62.87 ± 60.308 |
| Vitamin D nmol/L Week 13 | 78.42 ± 58.952 | 94.84 ± 56.849 |
| Vitamin D nmol/L Change from Baseline | 7.63 ± 79.383 | 20.65 ± 44.394 |
| Vitamin K nmol/L Baseline | 31.22 ± 84.315 | 0.21 ± 0.133 |
| Vitamin K nmol/L Week 13 | 14.64 ± NA | — |
| Vitamin K nmol/L Change from Baseline | -241.14 ± NA | — |
BID=twice daily; QD=once daily. Systemic concentrations of maralixibat in plasma were determined at the following visits: * Approximately 2.5 hours after the morning dose at Week 0/Day 1 of dosing * Before dosing and \~2.5 hours after the morning dose at Week 6, Week 10, and Week 13 Stable dosing occurred at 300 μg/kg QD, 300 μg/kg BID and 600 μg/kg BID for PFIC or at the highest tolerated dose. Note: The values added in section Measured Values are for maralixibat dose of 600 µg/kg BID.
| ng/mL | Maralixibat: PFIC |
|---|---|
| Maximum Level of Maralixibat Concentration in Plasma From Baseline to Week 13 for PFIC | 0.153 ± 0.2629 |
Collected over The timeframe for reporting adverse events was from Baseline to study week 147.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maralixibat: ALGS | 0/17 (0%) | 6/17 (35.3%) | 16/17 (94.1%) |
| Maralixibat: PFIC | 0/10 (0%) | 2/10 (20%) | 10/10 (100%) |
| Event | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| Intestinal obstructionGastrointestinal disorders | 0/17 | 1/10 |
| Abdominal sepsisInfections and infestations | 0/17 | 1/10 |
| Adenovirus infectionInfections and infestations | 0/17 | 1/10 |
| Appendicitis perforatedInfections and infestations | 0/17 | 1/10 |
| Gastroenteritis adenovirusInfections and infestations | 0/17 | 1/10 |
| InfluenzaInfections and infestations | 0/17 | 1/10 |
| CryingGeneral disorders | 1/17 | 0/10 |
| PyrexiaGeneral disorders | 1/17 | 0/10 |
| DiarrhoeaGastrointestinal disorders | 1/17 | 0/10 |
| Infantile colicGeneral disorders | 1/17 | 0/10 |
| Event | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| VomitingGastrointestinal disorders | 2/17 | 5/10 |
| DiarrhoeaGastrointestinal disorders | 7/17 | 4/10 |
| NasopharyngitisInfections and infestations | 6/17 | 4/10 |
| Upper respiratory tract infectionInfections and infestations | 4/17 | 4/10 |
| Viral infectionInfections and infestations | 4/17 | 4/10 |
| InvestigationsInvestigations | 3/17 | 3/10 |
| CoagulopathyBlood and lymphatic system disorders | 0/17 | 3/10 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 2/17 | 3/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/17 | 2/10 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 4/17 | 2/10 |
| Age, Customized(Participants) | Maralixibat :ALGS | Maralixibat: PFIC | Total |
|---|---|---|---|
| Preterm newborn - gestational age < 37 weeks | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 17 | 10 | 27 |
| Sex: Female, Male(Participants) | Maralixibat :ALGS | Maralixibat: PFIC | Total |
|---|---|---|---|
| Female | 3 | 3 | 6 |
| Male | 14 | 7 | 21 |
| Race (NIH/OMB)(Participants) | Maralixibat :ALGS | Maralixibat: PFIC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 7 | 6 | 13 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 9 | 4 | 13 |
| Region of Enrollment(participants) | Maralixibat :ALGS | Maralixibat: PFIC | Total |
|---|---|---|---|
| Belgium | 1 | 0 | 1 |
| United States | 6 | 1 | 7 |
| Poland | 4 | 3 | 7 |
| Brazil | 4 | 0 | 4 |
| United Kingdom | 2 | 3 | 5 |
| France | 2 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2021 to primary completion in Dec 2024, 39 months.
Results were first posted in Jun 2026, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maralixibat
Cholestasis, progressive familial intrahepatic 1 →